BioSpace News Archive

Alkermes plc announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration approval of VUMERITY™, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis, and Alkermes’ transfer to Biogen Inc. of the New Drug Application and other regulatory documentation related to VUMERITY.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced financial results for the third quarter ended September 30, 2019, and provided an update on recent company developments.

MEI Pharma, Inc., a late‐stage pharmaceutical company focused on advancing new therapies for cancer, announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET.

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, announced today that Moshe Mizrahy, Chairman and Chief Executive Officer, will present at the Canaccord Genuity MedTech & Diagnostics Forum at the Westin Grand Central, New York City on November 21st at 11:30 am EST.

Eagle Genomics is excited to announce its selection as a RisingFoodStar in the European Institute of Innovation and Technology Food’s (EIT Food) RisingFoodStars programme.

Pharmascience Inc. is proud to announce that the US Food and Drug Administration (FDA) communicated on October 31, 2019, that the abbreviated new drug application (ANDA) for Pharmascience’s generic version of Paliperidone Palmitate Extended-Release Injectable Suspension prefilled syringes, is accepted for review

Net sales increase 10.6% to $7,690,000, operating income was $409,000 for second quarter

UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, announced financial results for the third quarter ended September 30, 2019 and provided an overview of the Company’s recent developments.

Today in Nature Medicine, researchers from Barts Cancer Institute (London), Queen Mary University of London together with pathologists from HistoGeneX (Belgium), a laboratory focused on tissue pathology and genomics, published findings that may significantly alter the treatment of bladder cancer

Double-blind, placebo-controlled trial evaluating FDY-5301 for treatment of reperfusion injury following heart attack [12-November-2019] SEATTLE , Nov. 12, 2019 /PRNewswire/ -- Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced that top-line results from its Phase 2 t